Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Study With Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

NCT05318573 is registered in ClinicalTrials.gov with Fujifilm Pharmaceuticals U.S.A., Inc. as lead sponsor.

NCT NCT05318573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05318573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Study With Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Lead sponsor
Fujifilm Pharmaceuticals U.S.A., Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 1, 2022
Completion date
November 30, 2029
Enrollment
120 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non small cell lung cancer, advanced urothelial carcinoma